Curocell Company Description

Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals.

It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors.

The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T.

Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea.

Curocell Inc.

Country	South Korea
Founded	2016
Industry	Biological Products, Except Diagnostic Substances
CEO	Kim Gunsoo

Contact Details

Address: 11 Gukje Science 16-ro Daejeon, 34002 South Korea
Phone	82 4 2863 3698
Website	curocellbtx.com

Stock Details

Ticker Symbol	372320
Exchange	KOSDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836

Key Executives

Name	Position
Kim Gunsoo	Chief Executive Officer
Park Jin Kyong	Chief Financial Officer